Esperion Therapeutics (LTS:0IIM) 3-Year EBITDA Growth Rate : 30.70% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics 3-Year EBITDA Growth Rate?

Esperion Therapeutics's EBITDA per Share for the three months ended in Jun. 2024 was $-0.26.

During the past 3 years, the average EBITDA Per Share Growth Rate was 30.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 21.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -0.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Esperion Therapeutics was 46.00% per year. The lowest was -50.10% per year. And the median was 3.45% per year.

Competitive Comparison of Esperion Therapeutics's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Esperion Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's 3-Year EBITDA Growth Rate falls into.

Esperion Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Esperion Therapeutics (LTS:0IIM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Esperion Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ESPR:USA 0ET:Germany 0ET:Germany

Address

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108

Website

https://www.esperion.com

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics Headlines

No Headlines